Peter McWilliams, Chairman and CEO

Dr. McWilliams is the Chairman and Acting CEO of Liphorus Pharmaceuticals. He is a Managing Director with Sanderling Ventures and has more than twenty years of experience in biomedical research and management. He works actively with Sanderling portfolio companies in the role of Chairman, Director, CEO and member of the management team. In addition to Liphorus Pharmaceuticals, other portfolio companies include Actimis Pharmaceuticals (sold to Boehringer Ingelheim), Artielle Immunotherapeutics, Axikin Pharmaceuticals and Calcimedica. Prior to joining Sanderling, Dr. McWilliams worked at Genentech where, as a Product Manager in Oncology Commercial Development, he managed a pipeline of oncology products in clinical and pre-clinical development and was the Commercial Team Leader for Avastin. Prior to that he was an Associate with Booz & Co (now PwC) in San Francisco where he focused on consulting projects for major US and International life science companies. Prior to that he worked for Oxford Molecular, one of the first companies in the field of rational drug design and bio-informatics, where he helped to set up and establish their US operations prior to their successful IPO on the London Stock Exchange.

Dr. McWilliams received an M.B.A. from Columbia Business School, where he was an R.C. Kopf Fellow and was elected to Beta Gamma Sigma. He received a Ph.D. and M.A. in Chemistry from Princeton University where he received a Hugh Scott Taylor fellowship. He received a B.A. in Natural Sciences from Cambridge University.